Thelansis

Adrenocortical Carcinoma (ACC) Market Outlook Thelansis’s “Adrenocortical Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adrenocortical Carcinoma (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact o...

Adrenocortical Carcinoma (ACC) Market Outlook Thelansis’s “Adrenocortical Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adrenocortical Carcinoma (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Adrenocortical Carcinoma (ACC) Overview Adrenocortical carcinoma (ACC) is rare cancer that affects the adrenal gland and primarily affects individuals in early adulthood and between the ages of 40-50. Women are more commonly affected, comprising 55-60% of cases. The majority of ACC cases are of sporadic origin. However, they can also develop as part of familial diseases such as Beckwith-Wiedeman syndrome, Li-Fraum...

  Adrenocortical carcinoma (ACC) is a rare cancer that affects the adrenal gland and primarily affects individuals in early adulthood and between the ages of 40 and 50. Women are more commonly affected, comprising 55-60% of cases. The majority of ACC cases are of sporadic origin. However, they can also develop as part of familial diseases such as Beckwith-Wiedeman syndrome, Li-Fraumeni syndrome, Lynch syndrome, multiple endocrine neoplasia (MEN), and familial adenomatous polyposis (FAP). There are three main clinical presentations of ACC: hormone excess symptoms and signs in 40-60% of patients, non-specific symptoms due to local tumor growth such as abdominal or flank pain, abdominal fullness, or early satiety in a third of patients. Although the specific genetic alterations involved in ACC development are currently unknown, chromosomal abnormalities have been identified in hereditary neoplasia syndromes. The Wnt/β-catenin constitutive activation and insulin growth factor 2 (IGF2...